Item 2.02. Results of Operations and Financial Condition.



The information in this Item 2.02, including Exhibits 99.1 and 99.2 attached
hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as expressly set forth by
specific reference in such filing.

On May 11, 2020, AMAG Pharmaceuticals, Inc. (the "Company") issued a press
release regarding its operating results for the three months ended March 31,
2020 and its intention to hold a conference call to discuss the Company's first
quarter 2020 financial results and to give a business update. A copy of the
Company's press release is furnished herewith as Exhibit 99.1 and a copy of the
presentation slides to be used during the conference call is furnished herewith
as Exhibit 99.2.

Item 2.05. Costs Associated with Exit or Disposal Activities.



In May 2020, the Company announced a restructuring to reduce the size of its
organization in conjunction with the divestiture of Intrarosa and Vyleesi and
expected declines in its revenue due to the COVID-19 pandemic. Approximately
thirty percent of the workforce is being displaced through this workforce
reduction. The Company expects to record a one-time restructuring charge of
approximately $8 million primarily related to severance and related benefits in
the second quarter of 2020 and expects this workforce reduction to be
substantially completed by the end of the second quarter of 2020.

The charges that the Company expects to incur in connection with the workforce reduction are estimates and subject to a number of assumptions, and actual results may differ materially. The Company may incur additional costs not currently contemplated due to events associated with or resulting from the workforce reduction.

Item 4.01. Changes in Registrant's Certifying Accountant.

(a)


On May 8, 2020, the Company dismissed PricewaterhouseCoopers LLP ("PwC") as its
independent registered public accounting firm effective upon the Company's
filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020
with the U.S. Securities and Exchange Commission (the "SEC"). The decision to
dismiss PwC was approved by the Audit Committee of the Board of Directors of the
Company (the "Audit Committee") following a competitive process with several
independent registered public accounting firms, including PwC.

The reports of PwC on the Company's consolidated financial statements for each
of the two years ended December 31, 2019 and 2018 did not contain an adverse
opinion or disclaimer of opinion, nor were such reports qualified or modified as
to uncertainty, audit scope or accounting principles.

During the two most recent fiscal years and the subsequent interim period
through May 8, 2020, there were no disagreements (as defined in Item
304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of
Regulation S-K) between the Company and PwC on any matter of accounting
principles or practices, financial statement disclosure, or auditing scope or
procedure, which disagreement, if not resolved to the satisfaction of PwC, would
have caused PwC to make reference to the subject matter of such disagreement in
connection with its report. During the two most recent fiscal years and the
subsequent interim period through May 8, 2020, there was no "reportable event,"
as described in Item 304(a)(1)(v) of Regulation S-K.

The Company provided PwC with a copy of this Current Report on Form 8-K and
requested that PwC furnish a letter addressed to the SEC stating whether or not
it agrees with the statements made above therein. A copy of PwC's letter dated
May 11, 2020 is attached hereto as Exhibit 16.1.

(b)

On May 8, 2020, following completion of the competitive process described above, the Audit Committee appointed Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020, effective upon PwC's dismissal.



During the two most recent fiscal years and the subsequent interim period
through the date of this report, the Company has not consulted Deloitte with
respect to (a) the application of accounting principles to a specified
transaction, either completed or proposed, or the type of audit opinion that
might be rendered on the Company's consolidated financial statements, and
neither a written report was provided to the Company nor oral advice was
provided that Deloitte concluded was an important factor considered by the
Company in reaching a decision as to the accounting, auditing or financial
reporting issue; or (b) any matter
                                       2
--------------------------------------------------------------------------------

that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv)
of Regulation S-K and the related instructions to Item 304 of Regulation S-K),
or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).

Forward-Looking Statements



This report contains forward-looking information about the Company within the
meaning of the Private Securities Litigation Reform Act of 1995 and other
federal securities laws. Any statements contained herein or therein which do not
describe historical facts, including, among others, expectations for the
Company's restructuring initiative, including the expected charges, the timing
for incurring such charges and the timing for completing the workforce
reductions are forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those discussed in
such forward-looking statements.

Such risks and uncertainties include, among others, those risks identified in
the Company's filings with U.S. Securities and Exchange Commission (the
"Commission"), including its Annual Report on Form 10-K for the year ended
December 31, 2019, its Quarterly Reports, including its Quarterly Report on Form
10-Q for the quarter ended March 31, 2020, its Current Reports and subsequent
filings with the Commission, which are available at the Commission's website at
www.sec.gov. Any such risks and uncertainties could materially and adversely
affect the Company's results of operations, its profitability and its cash
flows, which would, in turn, have a significant and adverse impact on the
Company's stock price. The Company cautions you not to place undue reliance on
any forward-looking statements, which speak only as of the date they are made.
The Company disclaims any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.


Exhibit
Number                                                     Description
16.1                    Letter from PricewaterhouseCoopers to the

Securities and Exchange Commission, dated

May 11, 2020 (filed herewith)
99.1                    Press release issued by AMAG Pharmaceuticals, Inc.

on May 11, 2020 (furnished


                      herewith)
99.2                    Copy of AMAG Pharmaceuticals, Inc.'s presentation

slides dated May 11, 2020


                      (furnished herewith)
104                   Cover Page lnteractive Data File (embedded within the Inline XBRL document).




                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses